{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8","upperLimit":"617","value":"46.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"TTP was defined as the period from the day starting the first KW-0761 dosing to the day of PD identification (or the day of death if the subject died before PD was documented). Subjects were to be censored at the time of starting post-treatment, if it was started before PD identification.","dispersionType":"Full Range","groups":[{"description":"KW-0761 was administered 4 times at one-week intervals at a dose of 0.01, 0.1, 0.5 or 1.0 mg/kg in patients with CCR4 positive ATL or CCR4 positive PTCL.","id":"OG000","title":"KW-0761"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Baseline to response","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"days"}